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Cavernous sinus cavernous hemangioma (CSCH) is a relative-
ly rare benign lesion of the cavernous sinus. Despite its benign 
nature, it can manifest symptoms that can result from progres-
sive mass growth and compression of cranial nerves. CSCHs 
could be misdiagnosed as meningioma or schwannomas.1-5 
Magnetic resonance image (MRI) and red blood cell (RBC) scan 
are commonly used for differential diagnosis of these lesions.6
Surgical removal of CSCH can cause many morbidities or 
sometimes mortality due to increased mass vascularization; the 
surgical mortality rate associated with CSCH is reported to be 
38%.3 With advances in neurosurgical techniques, the risk is 
decreasing; however, surgical removal of CSCH is still challeng-
ing. Since its discovery, Gamma Knife surgery (GKS) has been 
widely used to manage CSCH and avoid the surgery-related 
risks. The purpose of this study was to evaluate the efficacy and 
safety of GKS treatment of CSCH with a specific focus on their 
relationship with radiological results and clinical outcomes.
This study included all adult patients (age >18 years) who un-
derwent stereotactic radiosurgery for a radiologically suspected 
CSCH between 2001 and 2017 at the Department of Neurosur-
gery, Severance Hospital, Yonsei University. Patients with in-
sufficient clinical data as well as patients with insufficient fol-
low-up time (less than 12 months) were excluded from the final 
analysis. 
All CSCHs were diagnosed based on radiologic findings, ex-
cept for one case of histopathologic diagnosis at the previous 
surgery. The diagnosis was made by experienced neuroradiol-
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Cavernous hemangiomas occur very rarely in the cavernous sinus. This study aimed to evaluate the efficacy of Gamma Knife sur-
gery (GKS) on cavernous sinus cavernous hemangioma (CSCH) and to analyze the temporal volume change. We retrospectively 
reviewed the clinical data of 26 CSCH patients who were treated with GKS between 2001 and 2017. Before GKS, 11 patients 
(42.3%) had cranial neuropathies and 5 patients (19.2%) complained of headache, whereas 10 patients (38.5%) were initially as-
ymptomatic. The mean pre-GKS mass volume was 9.3 mL (range, 0.5–31.6 mL), and the margin dose ranged from 13 to 15 Gy ac-
cording to the mass volume and the proximity to the optic pathway. All cranial neuropathy patients and half of headache patients 
showed clinical improvement. All 26 patients achieved mass control; remarkable responses (less than 1/3 of the initial mass vol-
ume) were shown in 19 patients (73.1%) and moderate responses (more than 1/3 and less than 2/3) in 7 patients (26.9%). The 
mean final mass volume after GKS was 1.8 mL (range, 0–12.6 mL). The mean mass volume at 6 months after GKS was 45% (range, 
5–80%) compared to the mass volume before GKS and 21% (range, 0–70%) at 12 months. The higher radiation dose tended to in-
duce more rapid and greater volume reduction. No treatment-related complication was observed during the follow-up period. 
GKS could be an effective and safe therapeutic strategy for CSCH. GKS induced very rapid volume reduction compared to other 
benign brain tumors.
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ogists based on typical MRI findings, including 1) high signal 
intensities on T2-weighted images, 2) strong delayed enhance-
ment after contrast injection, and 3) a round shape without a 
“dural tail” sign to exclude the possibility of meningioma.7,8 In 
cases where the diagnosis was difficult to confirm using MRI 
scan, labeled red blood cell pool scintigraphy (RBC scan) was 
used for differential diagnosis.6,7 This study showed progressive 
and persistent tracer accumulation of labeled RBCs in the le-
sion, establishing RBC scan as an effective method for the di-
agnosis of CSCH.6,7
Single-session GKS was provided to all of the patients using 
the Leksell Gamma Knife (Elekta Instrument AB, Stockholm, 
Sweden), Model B, C, or Perfexion. Following the frame fixation, 
a T1-weighted, three-dimensional, multiplanar, rapid-acquisi-
tion, gradient-echo MRI and a T2-weighted sequence were ob-
tained before and after gadolinium enhancement. Those imag-
es were exported to a computer workstation for dose planning 
using the Gamma Plan software (Elekta Instrument AB). The 
GKS dose was determined according to the proximity to the 
optic pathway and the mass volume calculated during the dose 
planning. Multiple isocenter planning method was applied to 
minimize the radiation exposure to the critical neuronal struc-
tures, such as the optic nerve.
All GKS were outpatient-based, and performed with a rou-
tine clinical follow-up schedule, as follows: clinical follow-up 
at 4 weeks after GKS, imaging follow-up at 6 and 12 months af-
ter GKS, and then annual follow-up. Specifically, in case of sus-
tained symptoms, imaging follow-up was performed, regard-
less of the scheduled timeline.
We evaluated the changes in mass volume, symptom improve-
ment, and adverse effects induced by GKS at regular follow-up. 
T1-weighted gadolinium-enhanced image and T2-weighted 
image were used for mass volume measurement. The mass vol-
ume change was defined as the ratio of the follow-up mass vol-
ume to the initial mass volume. “Remarkable response” was 
defined as the follow-up mass volume less than 1/3 of the initial 
mass volume, “moderate response” as the follow-up mass vol-
ume more than 1/3 and less than 2/3, and “minimal response” 
as the follow-up mass volume more than 2/3. As for the patient’s 
recovery, “complete recovery” was defined as the disappearance 
of symptoms before treatment, “partial recovery” as any im-
provement in clinical feature, and “no change” as no clinical 
deterioration or improvement observed after treatment.
We used the SPSS version 21.0 (IBM Corp., Armonk, NY, USA) 
for statistical analyses and the Wilcoxon paired t test to analyze 
the volume change data. P-value less than 0.05 was considered 
statistically significant.
Among the 29 patients who were treated by GKS, three pa-
tients missed a follow-up MRI due to general clinical improve-
ment, as they personally declared. As a result, they were exclud-
ed from this study, and a final total of 26 CSCH patients were 
included in this study. Among the 26 patients, GKS was per-
formed for 24 patients as a primary treatment, and a second-
ary treatment for two patients (one residual mass after surgical 
resection and one recurred mass after conventional radiation 
therapy). The median age of the patients at the time of treat-
ment was 54 years (range, 28–75 years), and the majority were 
female (n=20, 76.9%).
Patient demographics and outcomes are described in Table 1. 
Before treatment, 11 patients (42.3%) had cranial nerve dysfunc-
tion characterized by ptosis, diplopia, facial sense change, or 
vision change; and 5 patients (19.2%) experienced headache. 
In contrast, the remaining 10 patients (38.5%) were incidentally 
diagnosed during their workup for assessing other conditions, 
such as head injury. The mean clinical follow-up period was 
45.7 months (range, 12.1–131.1 months), and the mean mass 
volume before GKS was 9.3 mL (range, 0.5–31.6 mL). The mean 
marginal dose directed to the 50% isodose line was 13.7 Gy 
(range, 13–15 Gy). Clinical results showed good clinical out-
comes in all patients; 10 patients had “complete recovery,” 6 pa-
tients had “partial recovery,” and 10 patients had “no change.” 
Moreover, there was no recurrence or aggravation of symptoms 
during the follow-up period. None of the patients showed mini-
mal response, and all 26 patients achieved mass control; re-
markable responses were observed in 19 patients (73.1%), and 
moderate responses in 7 patients (26.9%). The mean mass vol-
ume at 6 months after GKS was 45% (range, 5–80%) of the mass 
volume before GKS and 21% (range, 0–70%) at 12 months. Post-
GKS MRI in 26 patients revealed a mean post-treatment mass 
volume of 1.8 mL (range, 0–12.6 mL), which was significantly 
lower than the pre-treatment volumes (p<0.05). Fig. 1 shows 









Follow-up duration (months) 45.7±27.7
Marginal dose (Gy) 13.7±0.6
Mass volume before GKS (mL) 9.3±7.3
Mass volume after GKS (mL) 1.8±2.9
Mass volume after GKS (%) 20.8±19.5
Radiologic results* (%)
Remarkable response (<1/3) 19 (73.1)
Moderate response (1/3–2/3) 7 (26.9)
Minimal response (>2/3) 0 (0.0)
Clinical results (%)
Complete recovery 10 (38.5)
Partial recovery 6 (23.1) 
No change 10 (38.5) 
GKS, Gamma Knife surgery.




temporal volume change after GKS during follow-up. 
Then, we classified the 26 patients into two groups accord-
ing to their radiologic results to identify the factors that influ-
ence mass volume change after GKS; 7 patients were classified 
as moderate remission group and 19 patients as remarkable 
remission group. We checked to see whether there were any 
significant differences between the two groups using the chi-
square or Student’s t-test (Table 2). Naturally, the mass volume 
after GKS showed a significant difference between the two groups 
(p=0.044, p<0.001). The marginal dose tended to be higher in the 
remarkable remission group than in the moderate remission 
group, but it did not reach statistical significance. We expect 
that if more sample sizes are secured, the results would have 
statistical significance. Other variables did not show statistical 
difference.
Cavernous hemangioma in cavernous sinus is a rarely pre-
sented lesion, which shares similar histologic, but different clini-
cal features with intracerebral lesions. Many well-known neu-
rosurgeons have reported their clinical experience of surgical 
removal of CSCHs, and specifically, suggested a total removal 
rate of 40–92.3%.2,8-11 Even though these surgeries were per-
formed by very experienced neurosurgeons, the reported post-
operative morbidity and mortality rates were as high as 80% 
and 20%, respectively.2,5,8,9,12 The reasons for the poor surgical 
outcomes were the high mass vascularization and deep location. 
Before the era of GKS, radiotherapy was considered as an al-
ternative treatment modality for avoiding the surgical risk. A 
number of studies have reported good clinical outcomes after 
radiotherapy, with a relatively high dose of radiation (>3 Gy) 
in fractions considered as an effective dose for CSCH manage-
ment.3,13-15 However, radiation therapy can cause complica-
tions in the central nervous system, especially after high-dose 
radiation. 
According to Iwai, et al.,16 CSCH was firstly treated with GKS 
in 1999. The patient was surgically treated at first, and then, GKS 
was performed for the residual lesion, resulting in good clini-
cal outcome. Following that case, many studies suggested that 
GKS could be an alternative to surgery or conventional radio-
therapy.17-22
Wang, et al.22 published the meta-analysis results of GKS for 
59 CSCH patients. Their study reported a remarkable mass 
shrinkage (more than 50%) in 40 patients (67.8%), partial shrink-
age (25–50%) in 15 patients (25.4%), and no change (less than 
25%) in 4 patients (6.8%). They also reported that there was no 
significant correlation between lesion volume and mass shrink-
age. However, patients with remarkable mass shrinkage were 
associated with higher prescription radiation dose (14 Gy vs. 
13.5 Gy, p=0.031).
Our study also demonstrated remarkable mass shrinkage 
during relatively early follow-up. Specifically, significant shrink-
age was observed in 19 patients (73.1%), clinical symptoms were 
relieved within a short period after GKS for about half of the 
patients (53.8%), and no complication related to GKS was not-
ed. These results were consistent with previous studies, and 
the rapid clinical improvement could be a result of rapid vol-
ume reduction (Fig. 2). 
The optimal radiation dose for mass control and symptom 
relief still remains debatable. The exposure to higher radiation 
doses facilitates higher rates of mass control, but it can nega-
tively affect critical structures around the cavernous sinus, such 
as the optic apparatus or cranial nerves. Therefore, the possibil-
ity of this complication usually limits the exposure to high ra-
diation doses.22 Our results showed that a higher radiation dose 
tended to induce earlier and greater volume reduction. 
Our study had several limitations. First, CSCHs were not diag-
nosed according to pathologic findings, but imaging findings. 
Therefore, there was a small possibility of misdiagnosis, and we 
tried to minimize the risk of misdiagnosis by performing RBC 
scan in case of difficult differentiation from other pathology. 












Male 1 (14.3) 5 (26.3)
Female 6 (85.7) 14 (73.7)
Age (yr) 60.5±10.7 52.8±13.8 0.201
Side (%) 1.000
Left 5 (71.4) 12 (63.2)
Right 2 (28.6) 7 (36.8)
Marginal dose (Gy) 13.3±0.5 13.8±0.6 0.069
Mass volume before GKS (mL) 10.2±10.2 8.9±6.2 0.698





GKS, Gamma Knife surgery.
Fig. 1. Temporal volume changes after GKS in 26 patients. The graph 
shows rapid mass decrease (within 6–12 months after GKS). The mass 
volume gradually decreased over 2 years, and no volume re-expansion 
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Second, as about half of the patients in our series were inciden-
tally diagnosed or had no cranial nerve deficit, the rationality 
of upfront GKS for these lesions could be controversial. Nev-
ertheless, the minimal invasiveness and higher safety of GKS 
could be a rationale for treating CSCHs that are incidentally 
found, as well.
Although surgical resection for CSCH is a curative treatment, 
it is not always easy and safe. Due to the highly radiosensitive 
nature of CSCH, GKS could be an effective and safe primary 
treatment modality for CSCH to prevent possible surgical com-
plications. Further studies should be performed to define the 
natural history of and optimal treatment guidelines for CSCH.
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Fig. 2. A 35-year-old female patient presented with incomplete right 6th cranial nerve palsy. T1-weighted (A) and T2-weighted images (B) showed a mass 
at the right cavernous sinus. Red blood cell scintigraphy (C) showed marked radioisotope uptake at the lesion, confirming the diagnosis of cavernous si-
nus cavernous hemangioma. The measured volume was 5.3 mL. After GKS (14 Gy of marginal dose at the 50% isodose line), all symptoms were resolved 
within 1 week. The 6-month follow-up magnetic resonance image showed remarkable decrease of the lesion (D), while the lesion could be hardly seen at 
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